Signaling Pathway Alterations Driven by BRCA1 and BRCA2 Germline Mutations are Sufficient to Initiate Breast Tumorigenesis by the PIK3CAH1047R Oncogene

dc.contributor.authorBhat-Nakshatri, Poornima
dc.contributor.authorKhatpe, Aditi S.
dc.contributor.authorChen, Duojiao
dc.contributor.authorBatic, Katie
dc.contributor.authorMang, Henry
dc.contributor.authorHerodotou, Christopher
dc.contributor.authorMcGuire, Patrick C.
dc.contributor.authorXuei, Xiaoling
dc.contributor.authorErdogan, Cihat
dc.contributor.authorGao, Hongyu
dc.contributor.authorLiu, Yunlong
dc.contributor.authorSandusky, George
dc.contributor.authorStorniolo, Anna Maria
dc.contributor.authorNakshatri, Harikrishna
dc.contributor.departmentSurgery, School of Medicine
dc.date.accessioned2024-05-21T09:31:39Z
dc.date.available2024-05-21T09:31:39Z
dc.date.issued2024
dc.description.abstractSingle-cell transcriptomics studies have begun to identify breast epithelial cell and stromal cell specific transcriptome differences between BRCA1/2 mutation carriers and non-carriers. We generated a single-cell transcriptome atlas of breast tissues from BRCA1, BRCA2 mutation carriers and compared this single-cell atlas of mutation carriers with our previously described single-cell breast atlas of healthy non-carriers. We observed that BRCA1 but not BRCA2 mutations altered the ratio between basal (basal-myoepithelial), luminal progenitor (luminal adaptive secretory precursor, LASP), and mature luminal (luminal hormone sensing) cells in breast tissues. A unique subcluster of cells within LASP cells is underrepresented in case of BRCA1 and BRCA2 mutation carriers compared with non-carriers. Both BRCA1 and BRCA2 mutations specifically altered transcriptomes in epithelial cells which are an integral part of NFκB, LARP1, and MYC signaling. Signaling pathway alterations in epithelial cells unique to BRCA1 mutations included STAT3, BRD4, SMARCA4, HIF2A/EPAS1, and Inhibin A signaling. BRCA2 mutations were associated with upregulation of IL6, PDK1, FOXO3, and TNFSF11 signaling. These signaling pathway alterations are sufficient to alter sensitivity of BRCA1/BRCA2-mutant breast epithelial cells to transformation as epithelial cells from BRCA1 mutation carriers overexpressing hTERT + PIK3CAH1047R generated adenocarcinomas, whereas similarly modified mutant BRCA2 cells generated basal carcinomas in NSG mice. Thus, our studies provide a high-resolution transcriptome atlas of breast epithelial cells of BRCA1 and BRCA2 mutation carriers and reveal their susceptibility to PIK3CA mutation-driven transformation. Significance: This study provides a single-cell atlas of breast tissues of BRCA1/2 mutation carriers and demonstrates that aberrant signaling due to BRCA1/2 mutations is sufficient to initiate breast cancer by mutant PIK3CA.
dc.eprint.versionFinal published version
dc.identifier.citationBhat-Nakshatri P, Khatpe AS, Chen D, et al. Signaling Pathway Alterations Driven by BRCA1 and BRCA2 Germline Mutations are Sufficient to Initiate Breast Tumorigenesis by the PIK3CAH1047R Oncogene. Cancer Res Commun. 2024;4(1):38-54. doi:10.1158/2767-9764.CRC-23-0330
dc.identifier.urihttps://hdl.handle.net/1805/40863
dc.language.isoen_US
dc.publisherAmerican Association for Cancer Research
dc.relation.isversionof10.1158/2767-9764.CRC-23-0330
dc.relation.journalCancer Research Communications
dc.rightsAttribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourcePMC
dc.subjectBRCA1 Protein
dc.subjectBRCA2 Protein
dc.subjectCarcinogenesis
dc.subjectGerm-line mutation
dc.subjectNuclear proteins
dc.subjectSignal transduction
dc.titleSignaling Pathway Alterations Driven by BRCA1 and BRCA2 Germline Mutations are Sufficient to Initiate Breast Tumorigenesis by the PIK3CAH1047R Oncogene
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
BhatNakshatri2024Signaling-CCBY.pdf
Size:
25.98 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: